"In May, Healthy Vision Month, the National Eye Institute (NEI) calls on Americans to make their vision a priority by taking the necessary steps to protect vision, prevent vision loss, and make the most of the vision they may have remaining."...
During the first two months following implantation, visual acuity loss of 3 lines or more, vitreous hemorrhage, and retinal detachments occurred in approximately 10-20% of patients. Cataract formation/lens opacities, macular abnormalities, intraocular pressure spikes, optic disk/nerve changes, hyphemas and uveitis occurred in approximately 1-5%.
Adverse events with an incidence of less than 1% were: retinopathy, anterior chamber cell and flare, synechia, hemorrhage (other than vitreous), cotton wool spots, keratopathy, astigmatism, endophthalmitis, microangiopathy, sclerosis, choroiditis, chemosis, phthisis bulbi, angle closure glaucoma with anterior chamber shallowing, vitreous detachment, vitreous traction, hypotony, severe post-operative inflammation, retinal tear, retinal hole, corneal dellen, choroidal folds, pellet extrusion from scleral wound, and gliosis.
Read the Vitrasert (ganciclovir) Side Effects Center for a complete guide to possible side effects
No drug interactions have been observed with the Vitrasert (ganciclovir) Implant. There is limited experience with use of retinal tamponades in conjunction with the Vitrasert (ganciclovir) Implant.
Read the Vitrasert Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 12/2/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Vitrasert Information
- Vitrasert Drug Interactions Center: ganciclovir io
- Vitrasert Side Effects Center
- Vitrasert FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.